Grundlæggende statistik
| LEI | 549300CPBME7Z3CYMN16 |
| CIK | 1494650 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OptiNose, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its chart |
|
| May 21, 2025 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF OPTINOSE, INC. a Delaware corporation Effective May 21, 2025 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments and Postponements 3 |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-273873 Registration No. 333-258707 Registration No. 333-228122 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273873 FORM S-3 REGISTRATION STATEMENT NO. 333-258707 FORM S-3 REGISTRATION STATEMENT NO. 333-22 |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-273873 Registration No. 333-258707 Registration No. 333-228122 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273873 FORM S-3 REGISTRATION STATEMENT NO. 333-258707 FORM S-3 REGISTRATION STATEMENT NO. 333-22 |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
Optn-form25 |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-225473 Registration No. 333-225416 Registration No. 333-220926 Registration No. 333-220515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 Registration Statement No. 333-225473 Post-Effective Amendment No. 1 to Form S-1 Registration State |
|
| May 21, 2025 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OPTINOSE, INC. May 21, 2025 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPTINOSE, INC. May 21, 2025 First: The name of the Corporation is OptiNose, Inc. (the “Corporation”). Second: The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington DE, 19808, New Castle County. The Corporation’s Registered Agent at such address is Corporation Serv |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-225473 Registration No. 333-225416 Registration No. 333-220926 Registration No. 333-220515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 Registration Statement No. 333-225473 Post-Effective Amendment No. 1 to Form S-1 Registration State |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-225473 Registration No. 333-225416 Registration No. 333-220926 Registration No. 333-220515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 Registration Statement No. 333-225473 Post-Effective Amendment No. 1 to Form S-1 Registration State |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-273873 Registration No. 333-258707 Registration No. 333-228122 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-273873 FORM S-3 REGISTRATION STATEMENT NO. 333-258707 FORM S-3 REGISTRATION STATEMENT NO. 333-22 |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-225473 Registration No. 333-225416 Registration No. 333-220926 Registration No. 333-220515 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 Registration Statement No. 333-225473 Post-Effective Amendment No. 1 to Form S-1 Registration State |
|
| May 21, 2025 |
Exhibit 99.1 Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies BOSTON, May 21, 2025 – Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, toda |
|
| May 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 21, 2025 As filed with the U.S. Securities and Exchange Commission on May 21, 2025 Registration No. 333-286111 Registration No. 333-277746 Registration No. 333-270333 Registration No. 333-263362 Registration No. 333-253814 Registration No. 333-236978 Registration No. 333-230083 Registration No. 333-223617 Registration No. 333-221047 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PO |
|
| May 16, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☐Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file numbe |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 3, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 3, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) OPTINOSE, INC. |
|
| March 26, 2025 |
Form of Indemnification Agreement INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of , 201 by and between OptiNose, Inc. |
|
| March 26, 2025 |
Form of Amended and Restated Pharmakon Warrant dated May 10, 2024 NEITHER THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMEN |
|
| March 26, 2025 |
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2024 XHANCE net revenue of $22. |
|
| March 26, 2025 |
EX-21.1 6 listofsubsidiariesex2112024.htm EX-21.1 Exhibit 21.1 OPTINOSE, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned OptiNose US, Inc. Delaware 100% |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, INC. (Exact n |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OptiNose, Inc. |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) OptiNose, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| March 26, 2025 |
EX-19.1 5 pol-finx005x04insidertra.htm EX-19.1 INSIDER TRADING POLICY TYPE OF DOCUMENT POL-FIN-005.04 EFFECTIVE DATE 17 JANUARY 2024 Page 1 of 12 Confidential - Not to be Distributed 1. PURPOSE OptiNose, Inc. (together with its subsidiaries, the “Company”) has adopted this Insider Trading Policy (this “Policy”) to prevent “insider trading”. Simply stated, insider trading occurs when a person uses |
|
| March 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| March 26, 2025 |
Description of Securities of OptiNose, Inc. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of OptiNose, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is our common st |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 20, 2025 |
Form of Director and Officer Voting Agreement. Exhibit 99.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement, dated as of March 19, 2025 (this “Agreement”), is by and between Paratek Pharmaceuticals, Inc., Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of OptiNose, Inc, a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings specified in t |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary proxy statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 20, 2025 |
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market - Acquisition advances Paratek’s vision to become a multi-product company focused on innovative specialty therapies - Total transaction value of up to ~$330 million - Potential consideration of up to $14 per share, including up front consideration of $9 per share, representing a 50% premium to Optinose’s closing trading price on March 19, 2025 BOSTON and Yardley, Pa. |
|
| March 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| March 20, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 (March 19, 2025) OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Or |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM DEFA14-A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) |
|
| March 20, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among OPTINOSE, INC. a Delaware corporation, PARATEK PHARMACEUTICALS, INC. a Delaware corporation, and ORCA MERGER SUB, INC., a Delaware corporation, Dated as of March 19, 2025 Table of Contents 1.1 The Closing 2 1.2 The Merger 2 1.3 Conversion of Shares 2 1.4 Surrender of Certificates; Stock Transfer Books 3 1.5 Dissenters’ Rights 6 1.6 Treatment of |
|
| March 20, 2025 |
Joint Press Release issued by OptiNose, Inc. and Paratek Pharmaceuticals, Inc. on March 19, 2025 Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market - Acquisition advances Paratek’s vision to become a multi-product company focused on innovative specialty therapies - Total transaction value of up to ~$330 million - Potential consideration of up to $14 per share, including up front consideration of $9 per share, representing a 50% premium to Optinose’s closing trading price on March 19, 2025 BOSTON and Yardley, Pa. |
|
| March 20, 2025 |
Exhibit 99.2 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement, dated as of March 19, 2025 (this “Agreement”), is by and between Paratek Pharmaceuticals, Inc., Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of OptiNose, Inc, a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings specified in t |
|
| March 20, 2025 |
Exhibit 99.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement, dated as of March 19, 2025 (this “Agreement”), is by and between Paratek Pharmaceuticals, Inc., Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of OptiNose, Inc, a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings specified in t |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 (March 19, 2025) OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Or |
|
| March 20, 2025 |
Exhibit 99.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement, dated as of March 19, 2025 (this “Agreement”), is by and between Paratek Pharmaceuticals, Inc., Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of OptiNose, Inc, a Delaware corporation (the “Company”). Capitalized terms used but not defined herein shall have the meanings specified in t |
|
| March 20, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among OPTINOSE, INC. a Delaware corporation, PARATEK PHARMACEUTICALS, INC. a Delaware corporation, and ORCA MERGER SUB, INC., a Delaware corporation, Dated as of March 19, 2025 Table of Contents 1.1 The Closing 2 1.2 The Merger 2 1.3 Conversion of Shares 2 1.4 Surrender of Certificates; Stock Transfer Books 3 1.5 Dissenters’ Rights 6 1.6 Treatment of |
|
| February 13, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EX-99 2 optinose99.htm EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amen |
|
| February 7, 2025 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| January 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| January 15, 2025 |
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22. |
|
| December 30, 2024 |
CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPTINOSE, INC. |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| December 23, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| November 20, 2024 |
OPTN / OptiNose, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G 1 optn13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Optinose, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68404V100 (CUSIP Number) November 13, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| November 14, 2024 |
OPTN / OptiNose, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINO |
|
| November 12, 2024 |
Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 12, 2024 2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U. |
|
| November 12, 2024 |
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q3 2024 XHANCE net revenue of $20. |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| October 18, 2024 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| October 18, 2024 |
OPTN / OptiNose, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindoptn13ga5sep.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 OptiNose, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68404V100 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| October 8, 2024 |
Optinose Appoints Terry Kohler as Chief Financial Officer Optinose Appoints Terry Kohler as Chief Financial Officer YARDLEY, Pa., Oct. 7, 2024 — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology thera |
|
| October 8, 2024 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of October 7, 2024 (the “Effective Date”), by and between OptiNose US, Inc. |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| August 8, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FIRST AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENT This FIRST AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENT (this “First Amendment”) is made as of June 7, 2024 (“First Amendment Effective Date”), by and between: HIKMA PHARMACEUTICALS USA INC. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, I |
|
| August 8, 2024 |
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q2 2024 XHANCE net revenue of $20. |
|
| August 8, 2024 |
Building a Leading ENT / Allergy Specialty Company Corporate Presentation August 8, 2024 2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U. |
|
| June 6, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| May 29, 2024 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| May 29, 2024 |
OPTN / OptiNose, Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 OptiNose, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68404V100 (CUSIP Number) May 10, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 20, 2024 |
AMENDMENT NO. 2 TO MANUFACTURE AND SUPPLY AGREEMENT This AMENDMENT NO. 2 TO MANUFACTURE AND SUPPLY AGREEMENT (this “Amendment”) is effective as of this 20th day of May, 2024 (the “Amendment Effective Date”), and is entered into by and between OptiNose US, Inc., duly organized and existing under the laws of Delaware and having offices located at 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 (r |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| May 14, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL MANUFACTURE AND SUPPLY AGREEMENT This MANUFACTURE AND SUPPLY AGREEMENT (the “Agreement”) is made as of December 11, 2020 (the “Effective Date”) by and between OptiNose US, Inc. |
|
| May 14, 2024 |
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q1 2024 XHANCE net revenue of $14. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, |
|
| May 14, 2024 |
Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 14, 2024 2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| May 9, 2024 |
\\4137-6534-5616 v1 Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $200,000,000. |
|
| May 9, 2024 |
Execution Version THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT This Third Amendment to the Note Purchase Agreement (defined below) (this “Amendment”), dated as of May 8, 2024 (the “Third Amendment Effective Date”), is entered into by and among OPTINOSE US, INC. |
|
| May 9, 2024 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 9, 2024 |
Form of Securities Purchase Agreement, dated May 8, 2024 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2024, between OptiNose Inc. |
|
| May 9, 2024 |
Form of Pre-Funded Warrant to Purchase Common Stock Execution Version FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: [•], 2024 OptiNose, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is entitled, |
|
| May 9, 2024 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 9, 2024 |
31,800,000 Shares of Common Stock Pre-Funded Warrants to Purchase 23,700,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273873 PROSPECTUS SUPPLEMENT (To Prospectus dated August 17, 2023) 31,800,000 Shares of Common Stock Pre-Funded Warrants to Purchase 23,700,000 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering in a registered direct offering to certain purchasers (i) 31,800,000 shares of our common s |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commiss |
|
| May 9, 2024 |
Optinose Announces $55 Million Registered Direct Offering Led by Nantahala Capital and The D. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 25, 2024 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| April 25, 2024 |
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14. |
|
| April 25, 2024 |
OPTN / OptiNose, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindoptn13ga3apr.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Optinose, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68404V100 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| April 25, 2024 |
Building a Leading ENT / Allergy Specialty Company Commercial Launch Call April 25, 2024 2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| March 15, 2024 |
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which frequently result in use of antibiotics XHANCE uses the proprietary Exhalation Delivery System to enable deposition of a proven steroid in target areas of inflammation deep in the nose not typically reached by standard nasal sprays Chronic sinusitis affects approximately 30 million adults in the U. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| March 8, 2024 |
SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT This Second Amendment to the Note Purchase Agreement (defined below) (this “Amendment”), dated as of March 8. |
|
| March 8, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| March 7, 2024 |
Form of Indemnification Agreement INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of , 201 by and between OptiNose, Inc. |
|
| March 7, 2024 |
among OptiNose US, Inc., OptiNose, Inc., and the purchaser parties thereto and BioPharma Credit PLC FIRST AMENDMENT AND WAIVER TO NOTE PURCHASE AGREEMENT This First Amendment and Waiver to the Note Purchase Agreement (defined below) (this “Amendment and Waiver”), dated as of March 5, 2024 (the “Effective Date”), is entered into by and among OPTINOSE US, INC. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| March 7, 2024 |
Exhibit 99.1 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps i |
|
| March 7, 2024 |
a20240307q4earningsprese Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 4 Exhibit 99. |
|
| March 7, 2024 |
OptiNose, Inc. Incentive Compensation Recovery Policy OPTINOSE, INC. INCENTIVE COMPENSATION RECOVERY POLICY (Adopted and approved on September 5, 2023, and effective as of October 1, 2023) 1. Purpose Optinose, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has ado |
|
| March 7, 2024 |
Exhibit 21.1 OPTINOSE, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned OptiNose US, Inc. Delaware 100% Optinose UK, Ltd. United Kingdom 100% |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) OptiNose, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, INC. (Exact n |
|
| March 7, 2024 |
Description of Securities of OptiNose, Inc. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of OptiNose, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is our common st |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OptiNose, Inc. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2024 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| February 22, 2024 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| February 22, 2024 |
OPTN / OptiNose, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindoptn13ga1feb.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Optinose, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68404V100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2024 |
MDWD / MediWound Ltd. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmdwd13ga14Feb2024.htm SC 13G Mediwound13G.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Title: Director, Rosalind |
|
| February 14, 2024 |
OPTN / OptiNose, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
OPTN / OptiNose, Inc. / ACORN BIOVENTURES, L.P. - OPTINOSE, INC. Passive Investment SC 13G/A 1 p24-0479sc13ga.htm OPTINOSE, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* OptiNose, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68404V100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 7, 2024 |
SC 13G/A 1 ea193003-13ga2kruttsch3opti.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* OptiNose, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68404V100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of th |
|
| January 30, 2024 |
OPTN / OptiNose, Inc. / Avista Capital Partners II GP, LLC - SC 13G/A Passive Investment SC 13G/A 1 d717880dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* OPTINOSE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 68404V100 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| December 21, 2023 |
Portions of this exhibit indicated by asterisks [**] have been omitted because they are not material and are the type of information that the registrant treats as private or confidential AMENDMENT NO. |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| December 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| December 6, 2023 |
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINO |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| November 9, 2023 |
Exhibit 99.1 Optinose Reports Third Quarter 2023 Financial Results and Operational Updates Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023 |
|
| November 9, 2023 |
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 9 , 2 0 2 3 Exhibit 99. |
|
| August 15, 2023 |
OPTINOSE, INC. 1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067 OPTINOSE, INC. 1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067 August 15, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: OptiNose, Inc. Registration Statement on Form S-3 Filed August 10, 2023 File No. 333-273873 Request for Acceleration of Effective Date Dear |
|
| August 10, 2023 |
CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OPTINOSE, INC. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, I |
|
| August 10, 2023 |
Exhibit 4.12 OPTINOSE, INC. and as Trustee INDENTURE Dated as of , ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Defined Terms 1 1.2 Other Definitions 5 1.3 Incorporation by Reference of Trust Indenture Act. 5 1.4 Rules of Construction. 6 ARTICLE 2 THE SECURITIES 6 2.1 Issuable in Series. 6 2.2 Establishment of Terms of Series of Securities 7 2.3 Execution and Authentication 9 2.4 Reg |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| August 10, 2023 |
=EXHIBIT 107 = Calculation of Filing Fee Table Form S-3 (Form Type) OptiNose, Inc. |
|
| August 10, 2023 |
a2023082earningspresenta Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 0 , 2 0 2 3 Exhibit 99. |
|
| August 10, 2023 |
Exhibit 99.1 Optinose Reports Second Quarter 2023 Financial Results and Operational Updates Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023 as SG&A and R&D expenses decreased by $22M or 33% compared to first half 2022 Conference call and webcast to b |
|
| July 28, 2023 |
OPTN / OptiNose Inc / Rosalind Advisors, Inc. - OPTINOSE INC. S13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Optinose, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 68404V100 (CUSIP Number) July 11, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d- |
|
| July 28, 2023 |
EX-99.A BD-DIR-RESOL 2 exa.htm EXHIBIT A JOINT FILING Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ornership of shares of Common Stock of OPTINOSE, INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Malter Fund L.P. By: Name: Mike McDonald Ti |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| July 27, 2023 |
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa., July 27, 2023— Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (E |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| June 13, 2023 |
Consulting Agreement, dated June 8, 2023, between OptiNose, Inc. and Joseph C. Scodari OptiNose US, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 June 8, 2023 Joseph C. Scodari [*home address omitted*] Dear Joe: This letter agreement, effective as of June 8, 2023 (this “Letter Agreement”) sets forth the terms and conditions under which OptiNose, Inc. (the “Company”) hereby engages you, Joseph C. Scodari (“you” or “Consultant”) as a consultant to the Company. By signing th |
|
| May 11, 2023 |
Exhibit 99.1 Optinose Reports First Quarter 2023 Financial Results and Operational Updates Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company reports first quarter 2023 XHANCE net revenue of $11.8 million Conference call and webcast to be held today at 8 |
|
| May 11, 2023 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, |
|
| May 11, 2023 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc. |
|
| May 11, 2023 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc. |
|
| May 11, 2023 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective as of May 9, 2023 (the “Effective Date”), by and between OptiNose US, Inc. |
|
| May 11, 2023 |
a20230511q1earningsprese Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 1 , 2 0 2 3 Exhibit 99. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commiss |
|
| May 4, 2023 |
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 17, 2023 |
a20230410optinosepresent Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n A p r i l 1 7 , 2 0 2 3 Exhibit 99. |
|
| April 17, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| March 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| March 7, 2023 |
a20230307q4earningsprese Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 3 EXHIBIT 99. |
|
| March 7, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) OptiNose, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| March 7, 2023 |
Exhibit 21.1 OPTINOSE, INC. LIST OF SUBSIDIARIES Name Jurisdiction of Incorporation Percent Owned OptiNose US, Inc. Delaware 100% Optinose AS Norway 100% Optinose UK, Ltd. United Kingdom 100% |
|
| March 7, 2023 |
Form of Indemnification Agreement. EX-10.1 3 formindemnificationagreeme.htm EX-10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is made as of , 201 by and between OptiNose, Inc., a Delaware corporation (the “Corporation”), in its own name and on behalf of its direct and indirect subsidiaries, and , an individual (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements be |
|
| March 7, 2023 |
Exhibit 99.1 Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and |
|
| March 7, 2023 |
Description of Securities of OptiNose, Inc. Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of OptiNose, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is our common st |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, INC. (Exact n |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OptiNose, Inc. |
|
| February 14, 2023 |
OPTN / OptiNose Inc / MVM Partners, LLC - MVM PARTNERS, LLC FORM SC 13D/A Activist Investment SC 13D/A 1 mvm13da.htm MVM PARTNERS, LLC FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* OPTINOSE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68404V100 (CUSIP Number) MVM Partners, LLC Old City Hall 45 School Street Boston, MA 02108 Attn: Eric Bednarski Troutman |
|
| February 14, 2023 |
OPTN / OptiNose Inc / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-optn123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTINOSE, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68404V100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| January 31, 2023 |
Form of Separation Agreement and General Release SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is made and entered into between Peter K. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| January 31, 2023 |
Optinose Announces CEO Transition and Business Update Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors YARDLEY, Pa. |
|
| January 31, 2023 |
, 2023, between Peter K. Miller and OptiNose US, Inc. OptiNose US, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 January 30, 2023 Peter K. Miller 237 Orchard Way Wayne, PA 19087 Dear Peter: This letter agreement (this “Letter Agreement”) sets forth then terms and conditions under which OptiNose US, Inc. (the “Company”) hereby engages you Peter K. Miller (“you” or “Consultant” as a consultant to the Company. By signing this letter, you acce |
|
| January 31, 2023 |
EX-10.1 2 a101amendedandrestatedempl.htm EX-10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on January 30, 2023 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US” and the “Company”), and Ramy A. Mahmoud (“Executive”). WHEREAS, Executive currently serves as the President & Ch |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* OptiNose, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 68404V100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to W |
|
| December 16, 2022 |
Consulting Agreement, dated December 16, 2022, between OptiNose US, Inc. and December 15, 2022 Michele Janis Janis Consulting LLC 131 Magnolia Drive Phoenixville, PA 19460 Dear Michele: This letter agreement (this ?Letter Agreement?) sets forth the terms and conditions under which OptiNose US, Inc. |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| December 15, 2022 |
Optinose Appoints Paul Spence as Chief Commercial Officer Optinose Appoints Paul Spence as Chief Commercial Officer YARDLEY, Pa., Dec. 15, 2022 Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestl? Healt |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| December 15, 2022 |
Employment Agreement, dated December 15, 2022, between OptiNose US, Inc. and Paul Spence, Jr. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on December 15, 2022 (the ?Effective Date?), by and between OptiNose US, Inc. |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Co |
|
| December 5, 2022 |
OPTN / OptiNose Inc / ACORN BIOVENTURES, L.P. - OPTINOSE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OptiNose, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68404V100 (CUSIP Number) November 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 1, 2022 |
OPTN / OptiNose Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 23, 2022 |
Optinose Announces Pricing of Public Offering of Common Stock and Warrants Optinose Announces Pricing of Public Offering of Common Stock and Warrants YARDLEY, Pa. |
|
| November 23, 2022 |
EXECUTION VERSION WARRANT AGENCY AGREEMENT THIS WARRANT AGENCY AGREEMENT (this ?Warrant Agreement?) is made as of November 23, 2022 (?Issuance Date?), between OptiNose, Inc. |
|
| November 23, 2022 |
26,320,000 shares of Common Stock Warrants to purchase up to 26,320,000 shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-258707 PROSPECTUS SUPPLEMENT (To Prospectus dated August 31, 2021) 26,320,000 shares of Common Stock and Warrants to purchase up to 26,320,000 shares of Common Stock We are offering 26,320,000 shares of our common stock and warrants to purchase up to 26,320,000 shares of our common stock (and the common stock issuable from time to time upon exe |
|
| November 23, 2022 |
AMENDED AND RESTATED JOINT FILING AGREEMENT Exhibit 1 AMENDED AND RESTATED JOINT FILING AGREEMENT The undersigned acknowledge and agree that the statement on Schedule 13D with respect to the beneficial ownership by the undersigned of the Common Stock of OptiNose, Inc. |
|
| November 23, 2022 |
26,320,000 Shares of Common Stock and Warrants to Purchase 26,320,000 Shares of Common Stock OptiNose, Inc. |
|
| November 23, 2022 |
Optinose Announces Proposed Public Offering of Common Stock and Warrants Optinose Announces Proposed Public Offering of Common Stock and Warrants YARDLEY, Pa. |
|
| November 23, 2022 |
OPTN / OptiNose Inc / MVM Partners, LLC - MVM PARTNERS LLC FORM 13D/A OPTN Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* OPTINOSE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 68404V100 (CUSIP Number) MVM Partners, LLC Old City Hall 45 School Street Boston, MA 02108 Attn: Eric Bednarski Troutman Pepper Hamilton Sanders LLP 400 Berwyn Park 899 Cassatt |
|
| November 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| November 23, 2022 |
Form of Common Stock Warrant issued by OptiNose, Inc. on November 23, 2022 OPTINOSE, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No. Number of Shares: Date of Issuance: November 23, 2022 (?Issuance Date?) CUSIP: 68404V118 OptiNose, Inc. a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, or its permitted assigns (the ?Holder?), is entitled, subject to t |
|
| November 21, 2022 |
shares of Common Stock Warrants to purchase up to shares of Common Stock The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 21, 2022 |
Execution Version NEITHER THIS AMENDED AND RESTATED NOTE PURCHASE AGREEMENT NOR THE NOTES ISSUED HEREUNDER HAVE BEEN REGISTERED PURSUANT TO THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR QUALIFIED PURSUANT TO ANY APPLICABLE STATE SECURITIES LAW. |
|
| November 21, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| November 10, 2022 |
Execution Version WAIVER TO NOTE PURCHASE AGREEMENT This Waiver to the Note Purchase Agreement (defined below) (this ?Waiver?), dated as of November 9, 2022 (the ?Effective Date?), is entered into by and among OPTINOSE US, INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (C |
|
| November 10, 2022 |
Form of Indemnification Agreement. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 201 by and between OptiNose, Inc. |
|
| November 10, 2022 |
THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT This Third Amendment to the Note Purchase Agreement (defined below) (this ?Amendment?), dated as of August 10, 2022 (the ?Effective Date?), is entered into by and among OPTINOSE US, INC. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINO |
|
| November 10, 2022 |
Exhibit 99.1 Optinose Reports Third Quarter 2022 Financial Results and Operational Updates Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE?s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Company reports third quarter 2022 XHANCE net r |
|
| November 10, 2022 |
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 1 0 , 2 0 2 2 Exhibit 99. |
|
| September 27, 2022 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on September 23, 2022 (the ?Effective Date?), by and between OptiNose US, Inc. |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) |
|
| September 27, 2022 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into on September 23, 2022, by and between OptiNose US, Inc. |
|
| September 23, 2022 |
1 Confidential Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would cause competitive harm to OptiNose, Inc. |
|
| September 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| August 11, 2022 |
Exhibit 99.1 Optinose Reports Second Quarter 2022 Financial Results and Operational Updates Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022 Company expects full year 2022 XHANCE net revenue to be between $85 to $92 million Company expec |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, I |
|
| August 11, 2022 |
Form of Indemnification Agreement. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 201 by and between OptiNose, Inc. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| August 11, 2022 |
THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT This Third Amendment to the Note Purchase Agreement (defined below) (this ?Amendment?), dated as of August 10, 2022 (the ?Effective Date?), is entered into by and among OPTINOSE US, INC. |
|
| August 11, 2022 |
a20220811q2earningsprese Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 2 2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U. |
|
| July 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| July 13, 2022 |
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ReOpen trials reveals 66% reduction in sinusitis exacerba |
|
| July 8, 2022 |
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from ReOpen2 indicate patients treated with XHANCE experienced improvement in symptoms and quality of life when compared to patients treated with placebo In pooled data from ReOpen1 and ReOpen2, XHANCE demonstrated a benefit relative to placebo on CT scans in patients with chronic sinusitis without nasal polyps YARDLEY, Pa. |
|
| July 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| July 1, 2022 |
TERMINATION LETTER June 30, 2022 BY ELECTRONIC MAIL OptiNose, Inc. 1020 Stony Hill Road, Suite 300 Yardley, PA 19067 Attn: Michael Marino, Chief Legal Officer Re: Termination of Stockholders? Agreement Dear Mr. Marino: Reference is hereby made to that certain Stockholders? Agreement, dated as of October 2, 2017 (the ?Stockholders? Agreement?), by and among OptiNose, Inc. (the ?Company?) and the Av |
|
| July 1, 2022 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| June 13, 2022 |
ReOpen2 Clinical Trial Top-Line Results J u n e 1 3 , 2 0 2 2 2 Forward-Looking Statements This presentation and our accompanying remarks contain ?forward-looking statements? within the meaning of the U. |
|
| June 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| June 13, 2022 |
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE?s Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients Conference call and webcast to be held today at 8:30 a. |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| June 3, 2022 |
Optinose Announces Departure of Chief Financial Officer Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer YARDLEY, Pa. |
|
| May 12, 2022 |
COOPERATION AGREEMENT This Cooperation Agreement (this ?Agreement?) is made and entered into as of April 25, 2022, by and among OptiNose, Inc. |
|
| May 12, 2022 |
Exhibit 99.1 Optinose Reports First Quarter 2022 Financial Results and Operational Updates Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021 Company expects top-line results from the second of two clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in June 2022 Conference call and webcast to be held today at |
|
| May 12, 2022 |
Form of Indemnification Agreement. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 201 by and between OptiNose, Inc. |
|
| May 12, 2022 |
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n May 1 2 , 2 0 2 2 2 Forward?Looking Statements This presentation and our accompanying remarks contain ?forward?looking statements? within the meaning of the U. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-38241 OPTINOSE, |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| April 26, 2022 |
Optinose Announces Appointment of R. John Fletcher to the Board Optinose Announces Appointment of R. John Fletcher to the Board YARDLEY, Pa., April 26, 2022? Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. "We are pleased to welcome John to the Optinose Board of Directors," |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 OPTINOSE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38241 42-1771610 (State or Other Jurisdiction of Incorporation or Organization) (Comm |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| April 26, 2022 |
DEFA14A 1 optnproxy2022additionalmat.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permit |
